GSK2269557
Sponsors
GlaxoSmithKline
Conditions
AsthmaCOPDPulmonary Disease, Chronic Obstructive
Phase 1
Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557
CompletedNCT01462617
Start: 2011-07-24End: 2012-03-26Updated: 2017-07-25
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects
CompletedNCT01762878
Start: 2013-01-09End: 2013-10-21Updated: 2017-07-13
Phase 2
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
CompletedNCT02294734
Start: 2015-03-31End: 2016-04-25Updated: 2021-08-12
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
CompletedNCT02522299
Start: 2015-11-04End: 2018-06-22Updated: 2021-09-05
A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (study 200879)
Active, not recruitingNL-OMON46452
Start: 2018-01-29Target: 41Updated: 2024-02-28